Blog
RSS FeedPosted by Michael Wonder on 03 Mar 2022
PRIME enables earlier availability of life-changing medicines
3 March 2022 - EMA’s PRIority Medicines (PRIME) scheme has had a positive impact on the authorisation of new medicines that ...
Posted by Michael Wonder on 19 Feb 2022
How digital therapeutics platforms are revolutionising health care delivery
17 February 2022 - With enormous advances in digital health innovation, we are quickly moving into an age where software platforms ...
Posted by Michael Wonder on 15 Feb 2022
MTAA welcomes patent box legislation
11 February 2022 - MTAA has welcomed the introduction of the Government’s Patent Box Bill into the House of Representatives ...
Posted by Michael Wonder on 10 Feb 2022
Patent box legislation to promote Australian innovation
11 February 2022 - Medicines Australia notes the introduction of patent box legislation, Treasury Laws Amendment (Tax Concession for Australian ...
Posted by Michael Wonder on 10 Feb 2022
Theragnostics announces that its radiotherapeutic for treatment of glioblastoma multiforme has been awarded UK's MHRA innovation passport
10 February 2022 - Promising non-clinical results support Phase 1 clinical study in recurrent glioblastoma multiforme. ...
Posted by Michael Wonder on 08 Dec 2021
Don’t destroy future drug development
8 December 2021 - With support faltering for the massive big-government blowout Congress is trying to jam through by Christmas, ...
Posted by Michael Wonder on 08 Dec 2021
New therapies for a range of conditions are coming in 2022
8 December 2021 - Haemophilia, brain disorders and malaria are being targeted. ...
Posted by Michael Wonder on 15 Nov 2021
Competing with, and learning from, China in the global pharmaceutical innovation race
15 November 2021 - President Joe Biden has promoted investment in technology based industries, including the life sciences, as a strategic ...
Posted by Michael Wonder on 14 Nov 2021
Regulating drug prices while increasing innovation
13 November 2021 - To save money on drugs while encouraging high-value pharmaceutical innovation, we need to better reward value, increase ...
Posted by Michael Wonder on 27 Oct 2021
FDA, NIH and 15 private organisations join forces to increase effective gene therapies for rare diseases
27 October 2021 - The U.S. FDA, the National Institutes of Health, 10 pharmaceutical companies and five non-profit organisations have partnered ...
Posted by Michael Wonder on 13 Oct 2021
Why we can have both innovative drugs and lower drug prices
13 October 2021 - The debate in Congress over negotiating drug prices is based on a phony premise that higher prices ...
Posted by Michael Wonder on 11 Oct 2021
Tegsedi receives innovative drug category pricing in Brazil
11 October 2021 - PTC Therapeutics today announced that Tegsedi (inotersen) has successfully received Category 1 classification from Câmara de ...
Posted by Michael Wonder on 11 Oct 2021
Medicare drug pricing debate pits savings against innovation
11 October 2021 - Proposal to allow Medicare to negotiate for lower prescription drug prices is central to Democrats’ health care, ...
Posted by Michael Wonder on 14 Sep 2021
Biden drug pricing plan seeks to balance access and innovation
13 September 2021 - On Thursday 9 September, Health and Human Services Secretary Xavier Becerra publicly released the Biden Administration’s ...
Posted by Michael Wonder on 18 Aug 2021
Pharmaceutical companies should pay for raiding nature's medicine cabinet
11 August 2021 - In 2019, the pharmaceutical industry profited from US$1·2 trillion of global spending on medicines. Most of this ...